9,608 results match your criteria Natriuretic Peptides in Congestive Heart Failure


Relationship of Natriuretic Peptides with Left Atrial Structure and Function within 1 Month after Electrical Cardioversion in Patients with Persistent Atrial Fibrillation.

Biomed Res Int 2019 17;2019:7636195. Epub 2019 Mar 17.

Department of Cardiology, Medical Academy, Lithuanian University of Health Sciences, Kaunas LT-50161, Lithuania.

Atrial fibrillation (AF) despite the absence of heart failure is related to increased levels of natriuretic peptides (NPs). NPs have not been widely investigated in relation to left atrium (LA) function after sinus rhythm (SR) restoration and duration of AF. The aim of the study was to determine the changes of NPs levels and to define their relation with LA phasic function after electrical cardioversion (ECV). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/7636195DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441525PMC

Sacubitril/Valsartan Decreases Cardiac Fibrosis in Left Ventricle Pressure Overload by Restoring PKG Signaling in Cardiac Fibroblasts.

Circ Heart Fail 2019 Apr;12(4):e005565

Department of Medicine, Aab Cardiovascular Research Institute (R.M.B., J.K.L., D.M.M., E.M.S.), University of Rochester, NY.

Background Heart failure (HF) is invariably accompanied by development of cardiac fibrosis, a form of scarring that increases muscular tissue rigidity and decreases cardiac contractility. Cardiac fibrosis arises from a pathological attempt to repair tissue damaged during maladaptive remodeling. Treatment options to block or reverse fibrosis have proven elusive. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/CIRCHEARTFAILURE.118.005565DOI Listing
April 2019
1 Read

Superior Prognostic Value of Right Ventricular Free Wall Compared to Global Longitudinal Strain in Patients With Heart Failure.

J Am Soc Echocardiogr 2019 Apr 9. Epub 2019 Apr 9.

Cardiology and Cardiovascular Pathophysiology, Azienda Ospedaliero-Universitaria "S. Maria della Misericordia", Perugia, Italy.

Background: Global right ventricular (RV) longitudinal strain (RVGLS) and free wall RV longitudinal strain (RVFWS) have both been advocated as sensitive tools to evaluate RV function and predict prognosis in patients with heart failure and reduced ejection fraction (HFrEF). However, because the interventricular septum is an integral part of the left ventricle (LV) also, RVGLS might be influenced by LV dysfunction. Thus, we compared the prognostic performance of either RV strain parameter in HFrEF patients, also taking into account the degree of LV systolic dysfunction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.echo.2019.02.011DOI Listing
April 2019
1 Read

Cross-Talk between Neurohormonal Pathways and the Immune System in Heart Failure: A Review of the Literature.

Int J Mol Sci 2019 Apr 5;20(7). Epub 2019 Apr 5.

Department of Pharmacy, University of Salerno, via Giovanni Paolo II 132, 84084 Fisciano (SA), Italy.

Heart failure is a complex clinical syndrome involving a multitude of neurohormonal pathways including the renin-angiotensin-aldosterone system, sympathetic nervous system, and natriuretic peptides system. It is now emerging that neurohumoral mechanisms activated during heart failure, with both preserved and reduced ejection fraction, modulate cells of the immune system. Indeed, these cells express angiotensin I receptors, adrenoceptors, and natriuretic peptides receptors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms20071698DOI Listing
April 2019
1 Read

The prognostic importance of subclinical heart failure in stable coronary heart disease patients.

Acta Cardiol 2019 Apr 3:1-8. Epub 2019 Apr 3.

a Faculty of Medicine in Pilsen , Charles University and University Hospital , Pilsen , Czech Republic.

Background: In stable coronary heart disease (CHD) patients we aimed to assess the predictive potential of only mild increase of brain natriuretic peptide (BNP) in subjects free from symptoms or diagnostic criteria of heart failure (HF).

Methods: We examined 967 patients, at least 6 months after myocardial infarction or coronary revascularization and divided them into three categories: 'overt HF' (NYHA II-IV, objective signs of HF, chronic treatment with furosemide and/or spironolactone or history of hospitalisation for HF), 'subclinical HF (BNP over 150 ng/mL, but no criterion of overt HF)' and 'no HF' (no above mentioned criterion present). Follow-up was done to assess 5-years all-cause mortality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/00015385.2019.1590958DOI Listing
April 2019
3 Reads

The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats.

Cardiovasc Diabetol 2019 Apr 1;18(1):45. Epub 2019 Apr 1.

Department of Medicine, Mackay Medical College, No.46, Sec. 3, Zhongzheng Rd., Sanzhi Dist., New Taipei City, 25245, Taiwan.

Background: Sodium glucose co-transporter 2 inhibitor (SGLT2i), a new class of anti-diabetic drugs acting on inhibiting glucose resorption by kidneys, is shown beneficial in reduction of heart failure hospitalization and cardiovascular mortality. The mechanisms remain unclear. We hypothesized that SGLT2i, empagliflozin can improve cardiac hemodynamics in non-diabetic hypertensive heart failure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0849-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444638PMC
April 2019
1 Read

Influence of Left Atrial Appendage Amputation on Natriuretic Peptides-A Randomized Controlled Trial.

Thorac Cardiovasc Surg 2019 Mar 31. Epub 2019 Mar 31.

Department of Adult and Pediatric Cardiovascular Surgery, Giessen University Hospital, Giessen, Germany.

Background:  Closure or amputation of the left atrial appendage (LAA) is a common therapy for atrial fibrillation (AF). As the LAA is a hormone-producing organ, however, amputation is still somewhat controversial. We examined patients after surgical AF therapy with or without LAA amputation to determine the influence of LAA amputation on pro-atrial natriuretic peptide (proANP) and B-type natriuretic peptide (BNP) plasma levels and on clinical severity of heart failure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0039-1683955DOI Listing
March 2019
5 Reads

Efficacy and safety of spironolactone in the heart failure with mid-range ejection fraction and heart failure with preserved ejection fraction: A meta-analysis of randomized clinical trials.

Medicine (Baltimore) 2019 Mar;98(13):e14967

Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Background: Recent studies have shown the efficacy for using spironolactone to treat heart failure with reduced ejection fraction (HFrEF), but the efficacy of spironolactone for heart failure with mid-range ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF) is unclear. This meta-analysis investigated the efficacy and safety of spironolactone in patients with HFmrEF and HFpEF.

Methods And Results: We searched several databases including PubMed and the Cochrane Collaboration, for randomized controlled trials (RCTs) that assessed spironolactone treatment in HFmrEF and HFpEF. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000014967DOI Listing
March 2019
1 Read

Clinical factors related to morbidity and mortality in high-risk heart failure patients: the GUIDE-IT predictive model and risk score.

Eur J Heart Fail 2019 Mar 27. Epub 2019 Mar 27.

Duke Clinical Research Institute, Durham, NC, USA.

Background: Most heart failure (HF) risk scores have been derived from cohorts of stable HF patients and may not incorporate up to date treatment regimens or deep phenotype characterization that change baseline risk over the short- and long-term follow-up period. We undertook the current analysis of participants in the GUIDE-IT (Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment) trial to address these limitations.

Methods And Results: The GUIDE-IT study randomized 894 high-risk patients with HF and reduced ejection fraction (≤ 40%) to biomarker-guided treatment strategy vs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1450DOI Listing

Relation between therapy-induced changes in natriuretic peptide levels and long-term therapeutic effects on mortality in patients with heart failure and reduced ejection fraction.

Eur J Heart Fail 2019 Mar 27. Epub 2019 Mar 27.

Division of Cardiology and the CardioVascular Center, Tufts Medical Center, Boston, MA, USA.

Aims: To assess whether natriuretic peptides (NPs) can be used to reliably predict long-term therapeutic effect on clinical outcomes for patients with heart failure and reduced ejection fraction (HFrEF).

Methods And Results: HFrEF intervention trials with mortality data were identified. Subsequently, we identified trials assessing therapy-induced changes in NPs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1411DOI Listing
March 2019
1 Read

Hjertesvikt med normal ejeksjonsfraksjon.

Tidsskr Nor Laegeforen 2019 Mar 22;139(6). Epub 2019 Mar 22.

Background: Approximately one half of all patients with heart failure have normal ejection fraction in the left ventricle, and heart failure is attributed to stiffness of the cardiac muscle. The most common cause is hypertension with ventricular hypertrophy.

Material And Method: Literature searches were conducted in PubMed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4045/tidsskr.18.0523DOI Listing

Atrial and brain natriuretic peptides- benefits and limits of their use in cardiovascular diseases.

Curr Cardiol Rev 2019 Mar 26. Epub 2019 Mar 26.

Department of Internal Medicine- Cardiology, Craiova University of Medicine and Pharmacy, Craiova 200349. Romania.

Natriuretic peptides, produced by cardiac myocytes, are regulators of the intravascular volume and blood pressure, also having neuroendocrine, metabolic and growth controlling effects. In heart failure, their synthesis increases exponentially as part of the neuroendocrine activation, but their beneficial effects are diminished. The paper reviews relevant data about their role as diagnosis and prognosis markers in heart failure, the hemodynamic and clinical benefits of their use as therapy in heart failure, together with the main adverse effects, information useful in daily clinical practice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1573403X15666190326150550DOI Listing
March 2019
6 Reads

Prognostic value of NT-proBNP added to clinical parameters to predict two-year prognosis of chronic heart failure patients with mid-range and reduced ejection fraction - A report from FAR NHL prospective registry.

PLoS One 2019 26;14(3):e0214363. Epub 2019 Mar 26.

Department of Cardiology, University Hospital Brno, Brno, Czech Republic.

Background: According to guidelines, the prognosis of patients with chronic heart failure can be predicted by determining the levels of natriuretic peptides, the NYHA classification and comorbidities. The aim our work was to develop a prognostic score in chronic heart failure patients that would take account of patients' comorbidities, NYHA and NT-proBNP levels.

Methods And Results: A total of 1,088 patients with chronic heart failure with reduced ejection fraction (HFrEF) (LVEF<40%) and mid-range EF (HFmrEF) (LVEF 40-49%) were enrolled consecutively. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0214363PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435170PMC
March 2019
5 Reads

Do the Natriuretic Peptides Cause Atrial Fibrillation or is it Not So Black and White?

J Am Heart Assoc 2019 Apr;8(7):e012242

1 Christchurch Heart Institute Christchurch New Zealand.

See Article by Whitman et al. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/JAHA.119.012242DOI Listing
April 2019
1 Read

BNP-Response to Acute Heart Failure Treatment Identifies High-Risk Population.

Heart Lung Circ 2019 Feb 26. Epub 2019 Feb 26.

Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, New York, NY, USA; Division of Hospital Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, New York, NY, USA. Electronic address:

Background: Using serial measurements of Brain Natriuretic Peptide (BNP) has been proposed as a method to guide therapy for patients treated for acute decompensated heart failure. However, 20-47% of patients do not achieve the target BNP thresholds despite treatment. We hypothesised that "BNP unresponsive" patients represent a distinct group at high risk for poor outcomes and sought to examine the characteristics and outcomes of this group. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hlc.2019.02.004DOI Listing
February 2019

Effect of Neprilysin Inhibition on Various Natriuretic Peptide Assays.

J Am Coll Cardiol 2019 Mar;73(11):1273-1284

Cardiology Division, Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts; Baim Institute for Clinical Research, Boston, Massachusetts. Electronic address:

Background: With sacubitril/valsartan treatment, B-type natriuretic peptide (BNP) concentrations increase; it remains unclear whether change in BNP concentrations is similar across all assays for its measurement. Effects of sacubitril/valsartan on atrial natriuretic peptide (ANP) concentrations in patients are unknown. Lastly, the impact of neprilysin inhibition on mid-regional pro-ANP (MR-proANP), N-terminal pro-BNP (NT-proBNP), proBNP, or C-type natriuretic peptide (CNP) is not well understood. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacc.2018.12.063DOI Listing
March 2019
2 Reads

Effects of sacubitril/valsartan on B-type natriuretic peptide circulating levels and loop diuretic dose in a case series of stabilized heart failure patients with left ventricular ejection fraction ≤35.

Curr Med Res Opin 2019 Mar 21. Epub 2019 Mar 21.

b Cardiac, Thoracic and Vascular Department , University of Pisa , Pisa , Italy.

Sacubitril/valsartan, an angiotensin receptor neprilysin inhibitor, was shown to improve outcome in patients with heart failure (HF) and reduced left ventricular ejection fraction (LVEF). There are reasons for believing that the concept of the lower the B-type natriuretic peptide (BNP) circulating level the better the prognosis, may no longer be correct in patients treated with sacubitril/valsartan, since sacubitril may interfere with BNP clearance. We reported a case series of ten patients with stable chronic HF and LVEF ≤35% (mean age: 64 ± 8 years; 30% female), referred to our outpatient HF clinic, treated with sacubitril/valsartan, in whom the global amelioration of NYHA class and LVEF coupled a clinically significant decrease in BNP levels and a reduction of loop diuretic dose. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/03007995.2019.1598702DOI Listing
March 2019
2 Reads

Real-world role of natriuretic peptides for diagnosis and prognostic assessment of patients with suspected heart failure.

Authors:
Simon Woldman

Eur Heart J Qual Care Clin Outcomes 2019 Mar 15. Epub 2019 Mar 15.

Consultant Cardiologist, Barts Heart Centre, St Bartholomew's Hospital, West Smithfield, London.

View Article

Download full-text PDF

Source
http://fdslive.oup.com/www.oup.com/pdf/production_in_progres
Publisher Site
http://dx.doi.org/10.1093/ehjqcco/qcz012DOI Listing
March 2019
6 Reads

The Irreplaceable Value of Laboratory Diagnostics: Four Recent Tests that have Revolutionized Clinical Practice.

Authors:
Giuseppe Lippi

EJIFCC 2019 Mar 1;30(1):7-13. Epub 2019 Mar 1.

Section of Clinical Biochemistry, University of Verona, Italy.

There is a common perception that laboratory medicine may be occasionally perceived as neglected discipline by clinicians, and that laboratory tests may be considered ordinary commodities. Although there is still debate on the real contribution of diagnostic testing in care pathways, many clinical diagnoses cannot be made without laboratory data. In support of evidence-based added value of laboratory diagnostics, this article aims to discuss the over-reaching contribution of some recent tests to the clinical decision making, and the unquestionable role they have played in revolutionizing clinical practice. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416815PMC

Molecular and clinical implications of natriuretic peptides in aortic valve stenosis.

J Mol Cell Cardiol 2019 Mar 14;129:266-271. Epub 2019 Mar 14.

Department of Clinical and Molecular Medicine, School of Medicine and Psychology, Sapienza University of Rome, Italy; IRCCS Neuromed, Pozzilli (Isernia), Italy. Electronic address:

Aortic valve stenosis (AS) is the most common heart valve disease in North America and Europe leading to an increased risk of heart failure and death. A multidisciplinary evaluation of symptoms, individual risk profile, echocardiographic parameters, biomarkers assessment is required for an appropriate clinical and therapeutic management of AS. The natriuretic peptides (NPs) represent an important biomarker for diagnostic, prognostic and therapeutic purposes in several cardiovascular diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.yjmcc.2019.03.011DOI Listing
March 2019
2 Reads

Physical Activity, Quality of Life, and Biomarkers in Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction (from the NEAT-HFpEF Trial).

Am J Cardiol 2019 Feb 23. Epub 2019 Feb 23.

Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

Although atrial fibrillation/atrial flutter (AF/AFL) and heart failure with preserved ejection fraction (HFpEF) frequently coexist, the influence of AF/AFL on physical activity, N-terminal pro-B-type natriuretic peptide (NT-proBNP), and quality of life in HFpEF is unclear and could have relevance to HFpEF trial design. We evaluated the association between AF/AFL and volitional physical activity, functional performance, NT-proBNP, and quality of life in patients with HFpEF in the Nitrate's Effect on Activity Tolerance (NEAT)-HFpEF trial. Of 99 patients with accelerometer data, 35 (35%) had AF/AFL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.amjcard.2019.02.025DOI Listing
February 2019
2 Reads
3.276 Impact Factor

Natriuretic Peptides in Clinical Practice.

Anatol J Cardiol 2019 Mar;21(Suppl 1):1-40

Department of Cardiology, Faculty of Medicine, Eskişehir Osmangazi University, Eskişehir-Turkey.

Natriuretic peptides have long been introduced into clinical practice. These biomarkers have certainly been shown to provide useful information in the diagnosis, prognosis and risk stratification in heart failure and also may have a role in the guidance of heart failure therapy. Although, there are some limitations in using of these markers such as lack of specificity, aging, renal dysfunction or obesity, among the huge number of candidates for heart failure biomarkers, only natriuretic peptides are currently widely used in daily clinical practice in heart failure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14744/AnatolJCardiol.2019.55623DOI Listing
March 2019
7 Reads

Measurement of circulating natriuretic peptides to identify community-based patients at risk of incident heart failure - should we?

Authors:
Iain Squire

Eur J Heart Fail 2019 Apr 8;21(4):460-461. Epub 2019 Mar 8.

NIHR Biomedical Research Centre, University of Leicester, Leicester, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1391DOI Listing

Biomarkers in Routine Heart Failure Clinical Care.

Card Fail Rev 2019 Feb;5(1):50-56

Department of Medicine, Sultan Qaboos University Hospital Muscat, Oman.

Heart failure is a clinical condition with complex pathophysiology that involves many different processes. Diagnosis is often difficult in patients presenting for the first time with breathlessness. Many biomarkers have been identified that are elevated in heart failure and their role in assessing prognosis has also been investigated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.15420/cfr.2018.27.2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396063PMC
February 2019

Natriuretic Peptides in Chronic Heart Failure.

Card Fail Rev 2019 Feb;5(1):44-49

Department of Cardiology, Maastricht University Medical Center Maastricht, the Netherlands.

Normal brain natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) levels are helpful in excluding chronic heart failure in the ambulatory setting, although they have been studied less well and possibly less accurately than in acute care. They may also be of help in screening patients at risk to intervene and reduce the development of heart failure. Natriuretic peptides are also excellent prognostic markers of chronic heart failure, but the clinical value of such prognostic information is less clear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.15420/cfr.2018.26.1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396059PMC
February 2019

B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial.

J Am Coll Cardiol 2019 Mar 4;73(11):1264-1272. Epub 2019 Mar 4.

Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts. Electronic address:

Background: Natriuretic peptides are substrates of neprilysin; hence, B-type natriuretic peptide (BNP) concentrations rise with neprilysin inhibition. Thus, the clinical validity of measuring BNP in sacubitril/valsartan-treated patients has been questioned, and use of N-terminal pro-B-type natriuretic peptides (NT-proBNP) has been preferred and recommended.

Objectives: The purpose of this study was to determine the prognostic performance of BNP measurements before and during treatment with sacubitril/valsartan. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S07351097193027
Publisher Site
http://dx.doi.org/10.1016/j.jacc.2019.01.018DOI Listing
March 2019
12 Reads

Heart-fatty acid binding protein in dogs with degenerative valvular disease and dilated cardiomyopathy.

Vet J 2019 Feb 7;244:16-22. Epub 2018 Dec 7.

Companion Animal Studies, University of Bristol, Langford House, Langford, Bristol BS40 5DU, United Kingdom.

The study objective was to investigate heart-fatty acid binding protein (HFABP) concentrations in dogs with degenerative valvular disease (MVD) and dilated cardiomyopathy (DCM), and its potential as a prognostic factor. Plasma HFABP, N-terminal pro brain natriuretic peptide (NTproBNP) and serum cardiac troponin I (cTnI) levels were measured in 21 control dogs, 23 dogs with MVD and 13 dogs with DCM, with repeated sampling at 1 and 3 months after initial presentation. All dogs were followed up after 6 and 12 months to verify survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tvjl.2018.11.017DOI Listing
February 2019
2 Reads

Diastolic dysfunction in asymptomatic hemodialysis patients in the light of the current echocardiographic guidelines.

Int J Cardiovasc Imaging 2019 Feb 27;35(2):313-317. Epub 2019 Feb 27.

Department of Nephrology, General University Hospital, First Faculty of Medicine, Charles University, Prague, Czech Republic.

The prevalence of the left ventricular hypertrophy (LVH) is very high in end-stage renal disease treated by hemodialysis. Diastolic dysfunction is a frequent consequence and leads to the development of heart failure with preserved ejection fraction. New American/European echocardiographic guidelines for the assessment of diastolic function simplified the evaluation and were published recently. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10554-019-01564-2DOI Listing
February 2019
3 Reads

The Relationship of Appetite-Regulating Hormones in the Development of Cardiac Cachexia.

Int Heart J 2019 Mar 22;60(2):384-391. Epub 2019 Feb 22.

Laboratory of Cardiovascular Medicine, Department of Internal Medicine, First Affiliated Hospital, Harbin Medical University.

The physiological control of appetite regulation involves circulating hormones with orexigenic (ghrelin) and anorexigenic (cholecystokinin) properties that induce alterations in energy intake via perceptions of hunger and satiety. We sought to investigate the relationship between appetite-regulating hormones and the cachexia associated with chronic heart failure.We randomized male Sprague-Dawley rats into myocardial infarction (MI) or sham operation (SO) groups. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1536/ihj.18-131DOI Listing
March 2019
2 Reads

[Heart failure in patients over 80 years old].

Presse Med 2019 Feb 22;48(2):143-153. Epub 2019 Feb 22.

AP-HP, hôpital Henri-Mondor, service de cardiologie, 94000 Créteil, France; Paris-Est-Créteil University (UPEC), IMRB Inserm U955, 94000 Créteil, France.

Heart failure (HF) is a clinical syndrome that associates clinical signs in people over 80 years of age, an increase in natriuretic peptides and abnormal cardiac structures that result from cardiac aging in many cases. The most common symptoms are grouped according to the acronym "EPOF" (shortness of breath, weight gain, edema, fatigue). Over the age of 80, comorbidities must be taken into account. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lpm.2019.02.001DOI Listing
February 2019
2 Reads

NT-proBNP is a weak indicator of cardiac function and haemodynamic response to exercise in chronic heart failure.

ESC Heart Fail 2019 Apr 20;6(2):449-454. Epub 2019 Feb 20.

Cardiovascular Research Centre, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.

Aims: N-terminal prohormone of brain natriuretic peptide (NT-proBNP) plays an important role in diagnosis and management of heart failure. The aim of the present study was to assess haemodynamic response to exercise and to evaluate the relationship between NT-proBNP, cardiac function, and exercise tolerance in chronic heart failure.

Methods And Results: A single-centre, cross-sectional pilot study recruited 17 patients with chronic heart failure with reduced left ventricular ejection fraction (age 67 ± 7 years) and 20 healthy volunteers (age 65 ± 12 years). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ehf2.12424DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437429PMC
April 2019
3 Reads

Molecular Implications of Natriuretic Peptides in the Protection from Hypertension and Target Organ Damage Development.

Int J Mol Sci 2019 Feb 13;20(4). Epub 2019 Feb 13.

Department of Clinical and Molecular Medicine, School of Medicine and Psychology, Sapienza University of Rome, 00189 Rome, Italy.

The pathogenesis of hypertension, as a multifactorial trait, is complex. High blood pressure levels, in turn, concur with the development of cardiovascular damage. Abnormalities of several neurohormonal mechanisms controlling blood pressure homeostasis and cardiovascular remodeling can contribute to these pathological conditions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms20040798DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6412747PMC
February 2019
2 Reads

Beyond clinical examination and natriuretic peptides: comprehensive quantification of congestion with ultrasound in ambulatory heart failure patients.

Eur J Heart Fail 2019 Feb 18. Epub 2019 Feb 18.

Department of Emergency Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1422DOI Listing
February 2019

NT-pro-BNP correlates with disease severity and predicts outcome in cerebral haemorrhage patients: Cohort study.

J Neurol Sci 2019 Apr 8;399:51-56. Epub 2019 Feb 8.

Internal Medicine Department, São João Hospital Centre, Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal; Stroke Unit, São João Hospital Centre, Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal; Department of Surgery and Physiology, Faculty of Medicine, University of Porto, Alameda Prof. Hernani Monteiro, 4200-319 Porto, Portugal.

Background: Intracerebral haemorrhage (ICH) is a devastating condition, with more than half of patients dying or becoming dependent after such an event. Natriuretic peptides, frequently used in the management of heart failure, have been shown to correlate with disease severity and prognosis in brain disorders. The aim of this study was to test the hypothesis that NT-pro-BNP correlates with disease severity and is an independent prognostic marker for non-traumatic ICH patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2019.02.014DOI Listing
April 2019
2.474 Impact Factor

Non-familial cardiomyopathies in Lebanon: exome sequencing results for five idiopathic cases.

BMC Med Genomics 2019 Feb 14;12(1):33. Epub 2019 Feb 14.

Department of Biochemistry and Molecular Genetics, American University of Beirut Faculty of Medicine and Medical Center (AUBMC), Phase I, 8th floor, Room C-823, PO Box 11-0236, Riad El-Solh, Beirut, 1107 2020, Lebanon.

Background: Cardiomyopathies affect more than 0.5% of the general population. They are associated with high risk of sudden cardiac death, which can result from either heart failure or electrical abnormalities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12920-019-0478-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6375196PMC
February 2019
6 Reads

The Role of Troponin for Acute Heart Failure.

Curr Heart Fail Rep 2019 Feb;16(1):21-31

Department of Emergency Medicine, Wayne State University School of Medicine, Detroit, MI, USA.

Purpose Of Review: To review the mechanisms, clinical interpretation, prognostic role, and future research regarding cardiac troponin (cTn) in the assessment of acute heart failure (AHF) patients presenting to the emergency department (ED).

Recent Findings: cTn has become a necessary component of the evaluation of AHF patients in the ED, largely because of its independently predictive value as a prognosticator of poor outcome. High-sensitivity assays (hs-cTn) may add risk stratification value beyond conventional assays, specifically with regard to identifying low-risk AHF patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11897-019-0420-5DOI Listing
February 2019

Potential and Limitations of Atrial Natriuretic Peptide as Biomarker in Pediatric Heart Failure-A Comparative Review.

Front Pediatr 2018 29;6:420. Epub 2019 Jan 29.

Institute of Clinical Pharmacy and Pharmacotherapy, Heinrich-Heine-University, Düsseldorf, Germany.

Although B-type Natriuretic Peptide (BNP), N-terminal-proBNP (NT-proBNP), and mid-regional-proANP (MR-proANP) are included in current guidelines on heart failure in adults, no guideline considering these biomarkers in pediatric heart failure is available. A new drug class of neprilysin inhibitors as fixed-dose combination (Sacubitril/valsartan) has been introduced and is currently being investigated in children suffering from heart failure. Atrial Natriuretic Peptide (ANP) is discussed as a more useful alternative to BNP because it may grants better insights into the effects of this treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fped.2018.00420DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361796PMC
January 2019
2 Reads

Serum Circulating miR-150 is a Predictor of Post-Acute Myocardial Infarction Heart Failure.

Int Heart J 2019 Mar 8;60(2):280-286. Epub 2019 Feb 8.

Experimental Teaching Center, School of Basic Medical Sciences, Zhejiang University.

Patients with ischemic heart disease are associated with poor prognosis, and their number has increased globally. Therefore, biomarkers that could predict post-acute myocardial infarction (AMI) heart failure (HF) would be helpful to guide appropriate treatment. Based on the diagnosis on admission and results of echocardiogram performed on admission and 1 year after discharge, the current study recruited 54 patients with post-AMI HF, 59 patients with post-AMI non-HF, and 59 healthy controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1536/ihj.18-306DOI Listing
March 2019
1 Read

Thrombospondin-2 as a Potential Risk Factor in a General Population.

Int Heart J 2019 Mar 8;60(2):310-317. Epub 2019 Feb 8.

Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine Kurume.

Serum thrombospondin-2 (TSP-2) is a glycoprotein expressed in the extracellular matrix (ECM), which increases during tissue remodeling. It has been shown in recent studies that TSP-2 is a useful predictor of cardiovascular death in patients with heart failure (HF). However, the clinical importance of serum TSP-2 levels in a general population is still unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1536/ihj.18-246DOI Listing
March 2019
6 Reads

Manifestations of and risk factors for acute myocardial injury after acute organophosphorus pesticide poisoning.

Medicine (Baltimore) 2019 Feb;98(6):e14371

Department of Emergency, The Second People's Hospital of Lianyungang, Lianyungang 222006, China.

This study aimed to explore the risk factors for acute myocardial injury (AMI) caused by acute organophosphorus pesticide poisoning (AOPP).The clinical data of 98 patients, who were treated in our hospital due to oral AOPP from April 2013 to April 2017, were retrospectively analyzed. These patients were divided into two groups: AMI group and control group. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000014371DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380665PMC
February 2019
5 Reads

Heart failure in the patient with diabetes: Epidemiology, aetiology, prognosis, therapy and the effect of glucose-lowering medications.

Diabetes Obes Metab 2019 Feb 5. Epub 2019 Feb 5.

Diabetes and Thyroid Associates, Birmingham, Alabama.

In people with type 2 diabetes the frequency of heart failure (HF) is increased and mortality from HF is higher than with non-diabetic HF. The increased frequency of HF is attributable to the cardiotoxic tetrad of ischaemic heart disease, left ventricular hypertrophy, diabetic cardiomyopathy and an extracellular volume expansion resistant to atrial natriuretic peptides. Activation of the renin-angiotensin-aldosterone system and sympathetic nervous systems results in cardiac remodelling, which worsens cardiac function. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dom.13652DOI Listing
February 2019
3 Reads

Prognostic implications of plasma volume status estimates in heart failure with preserved ejection fraction: insights from TOPCAT.

Eur J Heart Fail 2019 Feb 4. Epub 2019 Feb 4.

Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.

Aims: Plasma volume expansion is clinically and prognostically relevant in individuals with heart failure. Prior cohorts either excluded or had limited representation of patients with heart failure with preserved ejection fraction (HFpEF). We aimed to examine the relationship between calculated plasma volume status (PVS) and outcomes in HFpEF. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1407DOI Listing
February 2019
1 Read

Hyperuricemia predicts adverse clinical outcomes after cardiac resynchronization therapy.

Scand Cardiovasc J 2018 Oct 3;52(5):250-255. Epub 2019 Feb 3.

a Heart and Vascular Center, Semmelweis University , Budapest , Hungary.

Objectives: Changes in the levels of serum creatinine and N-terminal of prohormone brain natriuretic peptide (NT-proBNP) are useful risk markers after cardiac resynchronization therapy (CRT). The diagnostic value of changes in serum uric acid levels has been established in chronic heart failure, but no data are available on the prognostic value of hyperuricemia in a CRT population.

Design: We measured markers of renal function [creatinine, blood urea nitrogen (BUN) and uric acid] and NT-proBNP levels of 129 heart failure patients undergoing CRT in a prospective, observational study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14017431.2018.1499954DOI Listing
October 2018
1 Read

Increased Serum CA125 and Brain-Derived Neurotrophic Factor (BDNF) Levels on Acute Myocardial Infarction: A Predictor for Acute Heart Failure.

Med Sci Monit 2019 Feb 1;25:913-919. Epub 2019 Feb 1.

Department of Cardiology, Hebei General Hospital, Shijiazhuang, Hebei, China (mainland).

BACKGROUND This study was conducted to see whether increased values of serum CA125 and BDNF (brain-derived neurotrophic factor) on acute myocardial infarction (AMI) act as predictor for acute heart failure (AHF). MATERIAL AND METHODS Seventy-eight patients with clinically diagnosed cardiac function II-IV; and AHF were considered as the study group of this retrospective study and patients who had cardiac function I (without AHF) were considered the control group (n=82). The values of CA125 and BDNF were measured using enzyme-linked immunosorbent assay (ELISA) for developing the correlation with the Killip classification, and the diagnostic value of AHF. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12659/MSM.912642DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367886PMC
February 2019

The level of NT-proBNP in ambulatory patients with chronic heart failure with preserved ejection fraction of the left ventricle.

Ter Arkh 2018 Sep;90(9):68-72

Medical Center Ural, Department of the early diagnostic and treatment of chronic heart failure, Yekaterinburg, Russia.

Aim: The prevalence of chronic heart failure (CHF) remains high. Echocardiography is a reliable method of diagnosing heart failure. Determination of brain natriuretic peptide allows to identify patients with the most probable diagnosis of heart failure, which requires further instrumental examination of patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.26442/terarkh201890968-72DOI Listing
September 2018

Soluble neprilysin does not correlate with prognosis in pulmonary hypertension.

ESC Heart Fail 2019 Apr 25;6(2):291-296. Epub 2019 Jan 25.

Department of Cardiovascular Medicine, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295, Japan.

Aims: It has been reported that circulating soluble neprilysin (sNEP), which catalyses the degradation of several vasodilator peptides such as natriuretic peptides, predicts prognosis in heart failure patients with reduced ejection fraction. Hypoxia-induced decrease in NEP expression in lungs has been reported. However, the associations between sNEP and haemodynamic parameters, as well as the prognostic impact of sNEP in pulmonary hypertension (PH), remain unclear. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ehf2.12404
Publisher Site
http://dx.doi.org/10.1002/ehf2.12404DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437424PMC
April 2019
11 Reads

Prediction of incident heart failure by serum amino-terminal pro-B-type natriuretic peptide level in a community-based cohort.

Eur J Heart Fail 2019 Apr 18;21(4):449-459. Epub 2019 Jan 18.

University of Melbourne, Parkville, Australia.

Aims: We investigated which serum amino-terminal pro-B-type-natriuretic peptide (NT-proBNP) levels inform heart failure (HF) risk in a community-based population at increased cardiovascular disease (CVD) risk.

Methods And Results: Inclusion criteria were age ≥ 60 years with one or more of self-reported hypertension, diabetes, heart disease, abnormal heart rhythm, cerebrovascular disease, or renal impairment. Exclusion criteria were known HF, ejection fraction (EF) < 50%, or more than mild valve abnormality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1381DOI Listing
April 2019
5 Reads

Heart failure and chronic obstructive pulmonary disease: a review.

Acta Cardiol 2019 Jan 16:1-8. Epub 2019 Jan 16.

a Internal Medicine Clinic , Clinical Emergency Hospital of Bucharest , Bucharest , Romania.

Heart failure (HF) and chronic obstructive pulmonary disease (COPD) are important causes of morbidity and mortality worldwide. The association between the two conditions have significant systemic effects and a chronic, progressive evolution, affecting exercise tolerance and quality of life. The diseases share common risk factors, such as smoking, advanced age, and low-grade systemic inflammation. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/00015385.2018.1
Publisher Site
http://dx.doi.org/10.1080/00015385.2018.1559485DOI Listing
January 2019
12 Reads

Prognostic value of short-term follow-up B-type natriuretic peptide levels after hospital discharge in patients with acute myocardial infarction.

Int J Cardiol 2019 Jan 8. Epub 2019 Jan 8.

Division of Cardiology, Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea. Electronic address:

Background: Elevated B-type natriuretic peptide (BNP) levels in patients hospitalized for acute myocardial infarction (AMI) are associated with heart failure and mortality. However, the role of BNP after hospital discharge is not clear. Therefore, we assessed the relationship between short-term follow-up BNP levels and clinical outcomes including all-cause mortality and major adverse cardiovascular events (MACE) in patients with AMI after hospital discharge. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijcard.2019.01.026DOI Listing
January 2019
2 Reads

Qishenyiqi dripping pill improves ventricular remodeling and function in patients with chronic heart failure: A pooled analysis.

Medicine (Baltimore) 2019 Jan;98(2):e13906

Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Department of Cardiology, Shandong University Qilu Hospital, School of Basic Medical Sciences of Shandong University.

Background: Qishenyiqi dripping pill for chronic heart failure (CHF) remains controversial due to lack of high-quality trials. Therefore, we conduct this pooled-analysis to evaluate the efficacy and safety of Qishenyiqi in CHF patients.

Methods: We searched for randomized clinical trials for Qishenyiqi dripping pill in treating CHF up to August 2018 through China National Knowledge Infrastructure (CNKI), the PubMed Database, the Wanfang Database, the China Scientific Journal Database (VIP), and the Chinese Biomedicine Literature Service System. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000013906DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336621PMC
January 2019
16 Reads